DNAJA3 and metabolic syndrome: In summary, these findings facilitate the novel therapeutic strategies of GMI via activating DNAJA3 to promote mitochondrial homeostasis and subsequently to mediate muscle function enhancement, metabolic syndrome amelioration and sarcopenic obesity resistance.